One approach is to manufacture these negative regulators, for example the antiangiogenic functioning cleavage products, in order to use these therapeutically with patients in the form of a pharmaceutical. This has already been realised in the case of endostatin, however with the disadvantage that the genetically modified proteins, depending on the expression system used, show no exact consensus and 100% effectiveness in comparison to naturally occurring cleavage products.
The invention shows that antiangiogenic antithrombin III is also a cleavage product or protein with modified conformity derived from native antithrombin III. Since the tumour cells are capable of decomposing antithrombin or changing its conformation, the application of native antithrombin III in vivo leads to a reduction or a stoppage of growth through inhibition of the vascular growth.
This means that native antithrombin III can also be directly applied in therapy. An expensive, complex and time-consuming separate approval as a medicinal product is not necessary, since native antithrombin III is a medicine that can already be found on the market for the treatment of inflammation reactions. Experiments show that antithrombin III leads to a reduction in the growth of the blood vessels and thereby a reduction of the tumour. It is very suitable for application in tumour angiogenesis.
In vivo experiments with mice confirm this; a therapy with 50 mg/kg/day antithrombin III leads to a clear inhibition of angiogenesis through reduced microvessel density and finally causes a complete obstruction of the growth of the tumour.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Dr. Peter Stumpf
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
A study carried out by an international team of researchers and published in the journal Physical Review X shows that ion-trap technologies available today are suitable for building large-scale quantum computers. The scientists introduce trapped-ion quantum error correction protocols that detect and correct processing errors.
In order to reach their full potential, today’s quantum computer prototypes have to meet specific criteria: First, they have to be made bigger, which means...
Since 2016, German and Spanish researchers, among them scientists from the University of Göttingen, have been hunting for exoplanets with the “Carmenes”...
DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.
Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
18.12.2017 | Information Technology
18.12.2017 | Physics and Astronomy
18.12.2017 | Agricultural and Forestry Science